Journey Medical Corp (DERM) shareholders
Close on Nov 13, 2026Market cap $122.21MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Wasatch Advisors LP | 2,449,253 | 11.00% | 13G (passive) amendment | Sep 30, 2026 |
| Tang Capital Management, LLC Joint filing with Kevin Tang (8.00%) | 1,854,596 | 8.00% | 13G (passive) amendment | Mar 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of DERM | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Wasatch Advisors LP | 2,858,930 | 10.13% | $20.24M | +725,560 | 0.13% |
| Tang Capital Management LLC | 1,610,000 | 5.70% | $11.40M | – | 0.52% |
| Vanguard Capital Management LLC | 675,185 | 2.39% | $4.78M | −406,895 | 0.00% |
| Punch & Associates Investment Management, Inc. | 536,000 | 1.90% | $3.79M | New | 0.19% |
| Pale Fire Capital SE | 528,584 | 1.87% | $3.74M | +46,597 | 0.26% |
| Opaleye Management Inc. | 350,000 | 1.24% | $2.48M | −610,000 | 0.22% |
| Summit Financial, LLC | 346,748 | 1.23% | $2.45M | −33,059 | 0.03% |
| Jane Street Group, LLC | 320,021 | 1.13% | $2.27M | New | 0.00% |
| Diametric Capital, LP | 295,663 | 1.05% | $2.09M | +99,251 | 0.22% |
| Ikarian Capital, LLC | 251,436 | 0.89% | $1.78M | – | 0.19% |
| Renaissance Technologies LLC | 229,700 | 0.81% | $1.63M | −12,800 | 0.00% |
| Geode Capital Management, LLC | 216,004 | 0.77% | $1.53M | −247,198 | 0.00% |
| American Financial Group Inc | 180,000 | 0.64% | $1.27M | – | 0.45% |
| Trexquant Investment LP | 171,338 | 0.61% | $1.21M | +143,242 | 0.01% |
| Marshall Wace, Llp | 139,843 | 0.50% | $990.09K | New | 0.00% |
| J. Goldman & Co LP | 137,584 | 0.49% | $974.10K | −362,604 | 0.03% |
| Millennium Management LLC | 110,016 | 0.39% | $778.91K | −273,051 | 0.00% |
| BlackRock, Inc. | 100,981 | 0.36% | $714.95K | −871,881 | 0.00% |
| XTX Topco Ltd | 100,923 | 0.36% | $714.54K | +71,559 | 0.01% |
| Vanguard Fiduciary Trust Co | 94,729 | 0.34% | $670.68K | −42,977 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 71 | 11M | 37.8% | 23 / 19 | 23 / 23 | 3M | 4M |
| Q1 2026 | 72 | 12M | 42.0% | 13 / 32 | 18 / 17 | 3M | 2M |
| Q4 2025 | 77 | 11M | 39.1% | 17 / 34 | 14 / 7 | 3M | 0M |
| Q3 2025 | 68 | 9M | 30.8% | 17 / 22 | 16 / 5 | 2M | 0M |
| Q2 2025 | 56 | 6M | 23.0% | 25 / 14 | 11 / 7 | 2M | 1M |
| Q1 2025 | 38 | 5M | 18.0% | 6 / 17 | 7 / 5 | 1M | 0M |
| Q4 2024 | 37 | 4M | 13.4% | 7 / 11 | 9 / 6 | 2M | 0M |
| Q3 2024 | 36 | 2M | 7.6% | 7 / 8 | 10 / 4 | 0M | 0M |
| Q2 2024 | 35 | 2M | 8.4% | 13 / 6 | 6 / 11 | 1M | 0M |
| Q1 2024 | 33 | 2M | 6.4% | 9 / 12 | 7 / 12 | 1M | 0M |
| Q4 2023 | 36 | 1M | 4.8% | 19 / 11 | 3 / 4 | 1M | 2M |
| Q3 2023 | 21 | 2M | 7.6% | 5 / 6 | 7 / 3 | 1M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
69 funds held DERM in Q1 2026, 46% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of DERM | Value | % of fund | As of |
|---|---|---|---|---|---|
| Wasatch Micro Cap Fund | 1,295,173 | 4.59% | $9.17M | 1.36% | Jun 30, 2026 |
| Wasatch Micro Cap Value Fund | 788,173 | 2.79% | $5.58M | 1.44% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 470,426 | 1.67% | $3.33M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 186,966 | 0.66% | $1.32M | 0.00% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 105,535 | 0.37% | $665.93K | 0.00% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 104,017 | 0.37% | $656.35K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 50,931 | 0.18% | $360.59K | 0.02% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 41,381 | 0.15% | $261.11K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 28,610 | 0.10% | $180.53K | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Growth Index Fund | 19,126 | 0.07% | $120.69K | 0.01% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 14,064 | 0.05% | $88.74K | 0.00% | May 31, 2026 |
| Vanguard Balanced Index Fund | 10,418 | 0.04% | $73.76K | 0.00% | Jun 30, 2026 |
| Invesco NASDAQ Future Gen 200 ETF | 9,405 | 0.03% | $59.35K | 0.31% | May 31, 2026 |
| Small Cap Index Fund | 8,545 | 0.03% | $53.92K | 0.00% | May 31, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 7,375 | 0.03% | $52.22K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Claude Maraoui | President & CEO, Director | 2,435,990 | 8.63% | Apr 24, 2026 |
| Ramsey Alloush | Chief Operating Officer | 598,543 | 2.12% | Apr 24, 2026 |
| Joseph Benesch | CFO | 261,371 | 0.93% | Apr 24, 2026 |
| Miranda Jayne Toledano | Director | 168,618 | 0.60% | Jul 2, 2026 |
| Justin Adam Smith | Director | 231,618 | 0.82% | Jul 2, 2026 |
| Neil Herskowitz | Director | 168,618 | 0.60% | Jul 2, 2026 |
| Michael Cooper Pearce | Director | 67,173 | 0.24% | Jun 26, 2026 |
| Lindsay A. Rosenwald Md | Director | 397,616 | 1.41% | Jun 26, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Neil Herskowitz Director | Jul 1, 2026 | Award | +50,000 | – | – | 168,618 |
| Justin Adam Smith Director | Jul 1, 2026 | Award | +50,000 | – | – | 231,618 |
| Miranda Jayne Toledano Director | Jul 1, 2026 | Award | +50,000 | – | – | 168,618 |
| Miranda Jayne Toledano Director | Jun 25, 2026 | Award | +10,000 | – | – | 118,618 |
| Lindsay A. Rosenwald Md Director | Jun 25, 2026 | Award | +10,000 | – | – | 221,146 |
| Michael Cooper Pearce Director | Jun 25, 2026 | Award | +10,000 | – | – | 67,173 |
| Neil Herskowitz Director | Jun 25, 2026 | Award | +10,000 | – | – | 118,618 |
| Justin Adam Smith Director | Jun 25, 2026 | Award | +10,000 | – | – | 181,618 |
| Joseph Benesch CFO | Apr 22, 2026 | Award | +28,907 | – | – | 261,371 |
| Ramsey Alloush Chief Operating Officer | Apr 22, 2026 | Award | +46,863 | – | – | 598,543 |
| Claude Maraoui President & CEO, Director | Apr 22, 2026 | Award | +49,277 | – | – | 2,435,990 |
| Claude Maraoui President & CEO, Director | Aug 25, 2025 | Tax withholding | −10,877 | $7.47 | $81.25K | 2,386,713 |
| Claude Maraoui President & CEO, Director | Aug 25, 2025 | Option exercise | +1,250,000 | $0.07 | $87.50K | 2,397,590 |
| Neil Herskowitz Director | Aug 5, 2025 | Award | +20,000 | – | – | 108,618 |
| Miranda Jayne Toledano Director | Aug 5, 2025 | Award | +20,000 | – | – | 108,618 |
| Lindsay A. Rosenwald Md Director | Aug 5, 2025 | Award | +50,000 | – | – | 211,146 |
| Michael Cooper Pearce Director | Aug 5, 2025 | Award | +20,000 | – | – | 57,173 |
| Justin Adam Smith Director | Aug 5, 2025 | Award | +20,000 | – | – | 171,618 |
| Michael Cooper Pearce Director | Jun 25, 2025 | Award | +7,173 | – | – | 37,173 |
| Lindsay A. Rosenwald Md Director | Jun 25, 2025 | Award | +7,173 | – | – | 161,146 |
| Neil Herskowitz Director | Jun 25, 2025 | Award | +7,173 | – | – | 88,618 |
| Justin Adam Smith Director | Jun 25, 2025 | Award | +7,173 | – | – | 151,618 |
| Miranda Jayne Toledano Director | Jun 25, 2025 | Award | +7,173 | – | – | 88,618 |
| Joseph Benesch CFO | Jun 17, 2025 | Award | +28,907 | – | – | 232,464 |
| Claude Maraoui President & CEO, Director | Jun 17, 2025 | Award | +49,277 | – | – | 2,397,590 |
| Ramsey Alloush Chief Operating Officer | Jun 17, 2025 | Award | +46,863 | – | – | 551,680 |
| Joseph Benesch CFO | May 2, 2025 | Sale | −2,409 | $6.84 | $16.48K | 203,557 |
| Ramsey Alloush COO | May 2, 2025 | Sale | −2,857 | $6.84 | $19.54K | 504,817 |
| Claude Maraoui President & CEO, Director | May 2, 2025 | Sale | −4,834 | $6.84 | $33.06K | 2,348,313 |
| Claude Maraoui President & CEO, Director | Mar 11, 2025 | Sale | −49,271 | $5.01 | $246.85K | 2,003,147 |
| Claude Maraoui President & CEO, Director | Mar 7, 2025 | Sale | −14,905 | $5.01 | $74.67K | 2,052,418 |
| Claude Maraoui President & CEO, Director | Mar 6, 2025 | Sale | −25,551 | $5.04 | $128.78K | 2,067,323 |
| Claude Maraoui President & CEO, Director | Mar 5, 2025 | Sale | −18,147 | $5.13 | $93.09K | 2,092,874 |
| Claude Maraoui President & CEO, Director | Mar 4, 2025 | Sale | −28,901 | $5.04 | $145.66K | 2,111,021 |
| Claude Maraoui President & CEO, Director | Mar 3, 2025 | Sale | −23,508 | $5.19 | $122.01K | 2,139,922 |
| Joseph Benesch CFO | Feb 21, 2025 | Sale | −1,365 | $5.19 | $7.08K | 45,966 |
| Joseph Benesch CFO | Aug 1, 2024 | Sale | −9,324 | $5.47 | $51.00K | 47,331 |
| Joseph Benesch CFO | Jul 23, 2024 | Sale | −4,055 | $5.40 | $21.90K | 56,655 |
| Michael Cooper Pearce Director | Jul 19, 2024 | Award | +30,000 | – | – | 30,000 |
| Miranda Jayne Toledano Director | Jul 8, 2024 | Award | +9,728 | – | – | 81,445 |
| Neil Herskowitz Director | Jul 8, 2024 | Award | +9,728 | – | – | 81,445 |
| Justin Adam Smith Director | Jul 8, 2024 | Award | +9,728 | – | – | 144,445 |
| Lindsay A. Rosenwald Md Director | Jul 8, 2024 | Award | +9,728 | – | – | 153,973 |
| Joseph Benesch CFO | May 1, 2024 | Award | +80,000 | – | – | 205,966 |
| Claude Maraoui President & CEO, Director | May 1, 2024 | Award | +175,000 | – | – | 2,353,147 |
| Lindsay A. Rosenwald Md Director | Mar 25, 2024 | Buy | +10,000 | $3.04 | $30.40K | 144,245 |
| Lindsay A. Rosenwald Md Director | Mar 22, 2024 | Buy | +20,000 | $3.40 | $68.00K | 134,245 |
| Justin Adam Smith Director | Mar 22, 2024 | Buy | +30,000 | $3.47 | $104.10K | 134,717 |
| Claude Maraoui President & CEO, Director | Mar 22, 2024 | Buy | +10,000 | $3.48 | $34.80K | 2,163,430 |
| Joseph Benesch Interim CFO | Feb 22, 2024 | Sale | −2,450 | $3.75 | $9.19K | 60,710 |
| Joseph Benesch CFO | Jan 3, 2024 | Award | +80,000 | – | – | 125,966 |
| Claude Maraoui President & CEO, Director | Jan 3, 2024 | Award | +175,000 | – | – | 2,178,147 |
| Jeffrey Paley Director | Nov 28, 2023 | Sale | −1,745 | $5.22 | $9.11K | 70,727 |
| Jeffrey Paley Director | Nov 8, 2023 | Sale | −255 | $3.76 | $959 | 114,217 |
| Jeffrey Paley Director | Nov 7, 2023 | Sale | −2,245 | $3.48 | $7.81K | 114,472 |
| Justin Adam Smith Director | Oct 13, 2023 | Buy | +33,000 | $2.98 | $98.34K | 104,717 |
| Jeffrey Paley Director | Oct 6, 2023 | Buy | +15,000 | $2.98 | $44.70K | 72,472 |
| Jeffrey Paley Director | Sep 21, 2023 | Buy | +30,000 | $2.97 | $89.10K | 57,472 |
| Lindsay A. Rosenwald Md Director | Sep 6, 2023 | Buy | +100,000 | $2.23 | $223.00K | 114,245 |
| Claude Maraoui President & CEO, Director | Sep 6, 2023 | Buy | +26,044 | $2.52 | $65.63K | 2,153,430 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Journey Medical's stock actually held short. Settlement fails (shares not delivered on time) peaked at 16,031 shares on Sep 25, 2026 over the last 90 days.
See a number that looks wrong?